RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

NCT00410124 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

416

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: RAD001
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals